Medical/Pharmaceuticals
Kelun-Biotech Receives IND Approval for SKB103, a Novel TAA-PD-L1 Bispecific ADC
CHENGDU, China, March 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) today announced that the Investigational New Drug (IND) application for SKB103, its self-developed novel bispecific antibody-drug conjugate with combined T...
2026-03-24 17:24
5483
DualityBio (9606.HK) Announces 2025 Annual Results
HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. (Hong Kong Stock Exchange Code: 09606.HK, hereinafter referred to as "DualityBio" or the "Company"), a leading global clinical-stage innovative biopharmaceutical company, today announced its first annual results since listing...
2026-03-24 15:55
6105
Prestige Biopharma Announces Positive Topline Results from Comparative SAMSON-II Study for HD204, a Potential Biosimilar to Avastin (bevacizumab)
Primary endpoint of Overall Response Rate at Week 18 met, demonstrating clinical equivalence in patients with advanced non-squamous non-small cell lung cancer SINGAPORE, March 24, 2026 /PRNewswire/ -- Prestige Biopharma today announced positive topline results from its Phase 3 SAMSON-II study ev...
2026-03-24 11:32
4710
KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
* Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase. * R&D Expenses was approximately RMB1319.68 million. * Loss for the period was RMB381.97 million, adjusted annual loss[1] was approxim...
2026-03-24 10:44
6202
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
SUZHOU, China, March 24, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN026) in combination with albumin-bound docetaxel (HB1801) and chemothe...
2026-03-24 09:32
6747
The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China
* 73% of participants achieved Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W. SAN FRANCISCO and SUZHOU, China, March 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharma...
2026-03-24 08:00
5747
Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis
CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS SYDNEY, March 24, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, today announced dosing of the first participant in its Phas...
2026-03-24 05:30
6016
Ordering Both ESR and CRP Lab Tests Could Save Hospitals Millions Per Year -- New Study Challenges Notion the Tests are Interchangeable
Peer-reviewed economic analysis finds a combined ESR + CRP testing strategy
reduces misdiagnoses and delivers net cost savings compared to CRP alone
SMITHFIELD, R.I., March 24, 2026 /PRNewswire/ --
2026-03-24 04:32
5390
Sisram Medical Reports Solid Growth in 2025
Solid growth driven by strong performance in international markets, with the injectables business accelerating rapidly DAXXIFY shows promising results from initial commercialization in China, with expansion plans underway HONG KONG, March 23, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company"...
2026-03-23 22:56
9208
WuXi XDC Delivers Exceptional Performance in 2025, Reinforcing Global Leadership in Bioconjugate CRDMO
* Revenue increased by 46.7% YoY to RMB 5,944 million * Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 36.0%, a 5.4 percentage points increase compared to 2024 * Adjusted net profit increased by 69.9% YoY to RMB 1,559 million, with its margin of 26.2%, a 3.6 percen...
2026-03-23 21:15
7206
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, March 23, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begi...
2026-03-23 21:00
7798
Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery
CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine
("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven
drug discovery company, today announced the launch ofPandaClaw, a
transformative new feature of thePandaOmics
2026-03-23 20:30
5885
Cambrex Advances US and European Expansions
EAST RUTHERFORD, N.J., March 23, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the completion of initial engineering studies for its new, large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles ...
2026-03-23 20:00
6030
Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies
MELBOURNE, Australia, March 23, 2026 /PRNewswire/ -- Monash University and ClinChoice Inc, a leading global clinical Contract Research Organization (CRO) focused on innovative therapeutics, today announced a strategic partnership designed to fast-track early-phase clinical trials and bring ground...
2026-03-23 14:15
6742
Belief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients
SHANGHAI, March 23, 2026 /PRNewswire/ -- Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life Sciences the rights to commercialize its investigational pr...
2026-03-23 14:02
8942
Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 22, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and immune-oncology, today announ...
2026-03-23 11:14
6141
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China
SHANGHAI, March 23, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an Asset P...
2026-03-23 10:24
6112
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
SAN FRANCISCO and SUZHOU, China, March 22, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2026-03-23 08:00
4948
Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)
* Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet * WU-KONG 28 is the first and only phase 3 study to demonstrate meaningful benefits with an oral, once daily, chemo-...
2026-03-21 19:26
9050
Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
SHANGHAI, March 20, 2026 /PRNewswire/ -- Henlius (2696.HK) today announced its annual results for the year ended December 31, 2025. During the reporting period, the Company recorded revenue of RMB 6.6666 billion, representing a year-on-year increase of 16.5%, and net profit of RMB 0.8270 billion....
2026-03-20 21:21
13121
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 294 media titles]
2026-10-22 22:35
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 283 media titles]
2026-10-19 13:18
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 277 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 276 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
26993
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
22645
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
21112
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
20567